-
1
-
-
84863576788
-
An overview of targeted alpha therapy
-
Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumour Biol. 33, 573-590 (2012).
-
(2012)
Tumour Biol.
, vol.33
, pp. 573-590
-
-
Kim, Y.S.1
Brechbiel, M.W.2
-
2
-
-
78650719836
-
Current concepts and future directions in radioimmunotherapy
-
Lin FI, Iagaru A. Current concepts and future directions in radioimmunotherapy. Curr. Drug Discov. Technol. 7, 253-262 (2010).
-
(2010)
Curr. Drug Discov. Technol.
, vol.7
, pp. 253-262
-
-
Lin, F.I.1
Iagaru, A.2
-
3
-
-
78650991430
-
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
-
Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117, 45-52 (2011).
-
(2011)
Blood
, vol.117
, pp. 45-52
-
-
Leahy, M.F.1
Turner, J.H.2
-
4
-
-
84867787497
-
Radiolabeled antibodies for cancer imaging and therapy
-
Barbet J, Bardi? M, Bourgeois M et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol. Biol. 907, 681-697 (2012).
-
(2012)
Methods Mol. Biol.
, vol.907
, pp. 681-697
-
-
Barbet, J.1
Bardi, M.2
Bourgeois, M.3
-
5
-
-
84877301430
-
General overview of radioimmunotherapy of solid tumors
-
Navarro-Teulon I, Lozza C, P?egrin A, Viv? E, Pouget JP. General overview of radioimmunotherapy of solid tumors. Immunotherapy 5, 467-487 (2013).
-
(2013)
Immunotherapy
, vol.5
, pp. 467-487
-
-
Navarro-Teulon, I.1
Lozza, C.2
Pegrin, A.3
Viv, E.4
Pouget, J.P.5
-
6
-
-
33644834874
-
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission
-
DOI 10.1200/JCO.2005.02.5973
-
Verheijen RH, Massuger LF, Benigno BB et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24, 571-578 (2006). (Pubitemid 46655592)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.4
, pp. 571-578
-
-
Verheijen, R.H.1
Massuger, L.F.2
Benigno, B.B.3
Epenetos, A.A.4
Lopes, A.5
Soper, J.T.6
Markowska, J.7
Vyzula, R.8
Jobling, T.9
Stamp, G.10
Spiegel, G.11
Thurston, D.12
Falke, T.13
Lambert, J.14
Seiden, M.V.15
-
7
-
-
33644833474
-
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results
-
DOI 10.1200/JCO.2005.03.4082
-
Reardon DA, Akabani G, Coleman RE et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. 24, 115-122 (2006). (Pubitemid 46630502)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.1
, pp. 115-122
-
-
Reardon, D.A.1
Akabani, G.2
Coleman, R.E.3
Friedman, A.H.4
Friedman, H.S.5
Herndon II, J.E.6
McLendon, R.E.7
Pegram, C.N.8
Provenzale, J.M.9
Quinn, J.A.10
Rich, J.N.11
Vredenburgh, J.J.12
Desjardins, A.13
Guruangan, S.14
Badruddoja, M.15
Dowell, J.M.16
Wong, T.Z.17
Zhao, X.-G.18
Zalutsky, M.R.19
Bigner, D.D.20
more..
-
8
-
-
84875948186
-
Radioimmunotherapy for peritoneal cancers
-
Seidl C, Essler M. Radioimmunotherapy for peritoneal cancers. Immunotherapy 5, 395-405 (2013).
-
(2013)
Immunotherapy
, vol.5
, pp. 395-405
-
-
Seidl, C.1
Essler, M.2
-
9
-
-
23844507146
-
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody
-
DOI 10.1158/1078-0432.CCR-05-0211
-
Richman CM, Denardo SJ, O'Donnell RT et al. Highdose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin. Cancer Res. 11, 5920-5927 (2005). (Pubitemid 41170321)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.16
, pp. 5920-5927
-
-
Richman, C.M.1
DeNardo, S.J.2
O'Donnell, R.T.3
Yuan, A.4
Shen, S.5
Goldstein, D.S.6
Tuscano, J.M.7
Wun, T.8
Chew, H.K.9
Lara, P.N.10
Kukis, D.L.11
Natarajan, A.12
Meares, C.F.13
Lamborn, K.R.14
DeNardo, G.L.15
-
10
-
-
76349109469
-
Anti-prostatespecific membrane antigen-based radioimmunotherapy for prostate cancer
-
Tagawa ST, Beltran H, Vallabhajosula S et al. Anti-prostatespecific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116 (4 Suppl.), 1075-1083 (2010).
-
(2010)
Cancer
, vol.116
, Issue.4 SUPPL.
, pp. 1075-1083
-
-
Tagawa, S.T.1
Beltran, H.2
Vallabhajosula, S.3
-
11
-
-
84875965291
-
Radioimmunotherapy for hematopoietic cell transplantation
-
Jurcic JG. Radioimmunotherapy for hematopoietic cell transplantation. Immunotherapy 5, 383-394 (2013).
-
(2013)
Immunotherapy
, vol.5
, pp. 383-394
-
-
Jurcic, J.G.1
-
12
-
-
75749110617
-
MIRD pamphlet 22 (abridged): Radiobiology and dosimetry of alphaparticle emitters for targeted radionuclide therapy
-
Sgouros G, Roeske JC, McDevitt MR et al. MIRD pamphlet No. 22 (abridged): radiobiology and dosimetry of alphaparticle emitters for targeted radionuclide therapy. J. Nucl. Med. 51, 311-328 (2010).
-
(2010)
J. Nucl. Med.
, vol.51
, pp. 311-328
-
-
Sgouros, G.1
Roeske, J.C.2
McDevitt, M.R.3
-
14
-
-
84900439357
-
Zielgerichtete Radionuklidtherapie mit α-Emittern-Grundlagen experimentelle und erste klinische Studien
-
Seidl C, Senekowitsch-Schmidtke R. Zielgerichtete Radionuklidtherapie mit α-Emittern-Grundlagen, experimentelle und erste klinische Studien. Der Nuklearmediziner 31, 81-92 (2008).
-
(2008)
Der Nuklearmediziner
, vol.31
, pp. 81-92
-
-
Seidl, C.1
Senekowitsch-Schmidtke, R.2
-
15
-
-
35549000927
-
Targeted alpha-therapy: Past, present, future
-
Brechbiel MW. Targeted alpha-therapy: past, present, future? Dalton Trans. 21, 4918-4928 (2007).
-
(2007)
Dalton Trans.
, vol.21
, pp. 4918-4928
-
-
Brechbiel, M.W.1
-
16
-
-
24044539916
-
Cancer radioimmunotherapy with alpha-emitting nuclides
-
DOI 10.1007/s00259-005-1803-2
-
Couturier O, Supiot S, Degraef-Mougin M et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. Mol. Imaging 32, 601-614 (2005). (Pubitemid 41214204)
-
(2005)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.32
, Issue.5
, pp. 601-614
-
-
Couturier, O.1
Supiot, S.2
Degraef-Mougin, M.3
Faivre-Chauvet, A.4
Carlier, T.5
Chatal, J.-F.6
Davodeau, F.7
Cherel, M.8
-
17
-
-
84856275035
-
Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells
-
Franken NA, Hovingh S, Ten Cate R et al. Relative biological effectiveness of high linear energy transfer α-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells. Oncol. Rep. 27, 769-774 (2012).
-
(2012)
Oncol. Rep.
, vol.27
, pp. 769-774
-
-
Franken, N.A.1
Hovingh, S.2
Ten Cate, R.3
-
18
-
-
84856288224
-
H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues
-
Firsanov DV, Solovjeva LV, Svetlova MP. H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues. Clin. Epigenetics 2, 283-297 (2011).
-
(2011)
Clin. Epigenetics
, vol.2
, pp. 283-297
-
-
Firsanov, D.V.1
Solovjeva, L.V.2
Svetlova, M.P.3
-
19
-
-
84878410708
-
Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation
-
Wulbrand C, Seidl C, Gaertner FC et al. Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation. PLoS ONE 8, e64730 (2013).
-
(2013)
PLoS ONE
, vol.8
-
-
Wulbrand, C.1
Seidl, C.2
Gaertner, F.C.3
-
20
-
-
33947224658
-
213Bi]anti- CD45 antibodies in leukemia cells
-
DOI 10.1158/0008-5472.CAN-06-3569
-
Friesen C, Glatting G, Koop B et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res. 67, 1950-1958 (2007). (Pubitemid 46424211)
-
(2007)
Cancer Research
, vol.67
, Issue.5
, pp. 1950-1958
-
-
Friesen, C.1
Glatting, G.2
Koop, B.3
Schwarz, K.4
Morgenstern, A.5
Apostolidis, C.6
Debatin, K.-M.7
Reske, S.N.8
-
21
-
-
77952095165
-
In vitro experimental 211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin
-
Petrich T, Korkmaz Z, Krull D, Fr?ke C, Meyer GJ, Knapp WH. In vitro experimental 211At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Eur. J. Nucl. Med. Mol. Imaging 37, 851-861 (2010).
-
(2010)
Eur. J. Nucl. Med. Mol. Imaging
, vol.37
, pp. 851-861
-
-
Petrich, T.1
Korkmaz, Z.2
Krull, D.3
Frke, C.4
Meyer, G.J.5
Knapp, W.H.6
-
22
-
-
84878373820
-
The repair and signaling responses to DNA double-strand breaks
-
Goodarzi AA, Jeggo PA. The repair and signaling responses to DNA double-strand breaks. Adv. Genet. 82, 1-45 (2013).
-
(2013)
Adv. Genet.
, vol.82
, pp. 1-45
-
-
Goodarzi, A.A.1
Jeggo, P.A.2
-
23
-
-
84879953282
-
DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy
-
Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front. Oncol. 3, 113 (2013).
-
(2013)
Front. Oncol.
, vol.3
, pp. 113
-
-
Mladenov, E.1
Magin, S.2
Soni, A.3
Iliakis, G.4
-
24
-
-
84875198804
-
Chromatin remodeling at DNA double-strand breaks
-
Price BD, D'Andrea AD. Chromatin remodeling at DNA double-strand breaks. Cell 152, 1344-1354 (2013).
-
(2013)
Cell
, vol.152
, pp. 1344-1354
-
-
Price, B.D.1
D'Andrea, A.D.2
-
25
-
-
84876274744
-
Histone modifications and DNA double-strand break repair after exposure to ionizing radiations
-
Hunt CR, Ramnarain D, Horikoshi N et al. Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat. Res. 179, 383-392 (2013).
-
(2013)
Radiat. Res.
, vol.179
, pp. 383-392
-
-
Hunt, C.R.1
Ramnarain, D.2
Horikoshi, N.3
-
26
-
-
34548074399
-
2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe
-
DOI 10.1158/1535-7163.MCT-07-0132
-
Seidl C, Port M, Gilbertz KP et al. 213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe. Mol. Cancer Ther. 6, 2346-2359 (2007). (Pubitemid 47294763)
-
(2007)
Molecular Cancer Therapeutics
, vol.6
, Issue.8
, pp. 2346-2359
-
-
Seidl, C.1
Port, M.2
Gilbertz, K.-P.3
Morgenstern, A.4
Bruchertseifer, F.5
Schwaiger, M.6
Roper, B.7
Senekowitsch-Schmidtke, R.8
Abend, M.9
-
27
-
-
74149087930
-
Differential gene expression triggered by highly cytotoxic alpha-emitterimmunoconjugates in gastric cancer cells
-
Seidl C, Port M, Apostolidis C et al. Differential gene expression triggered by highly cytotoxic alpha-emitterimmunoconjugates in gastric cancer cells. Invest. New Drugs 28, 49-60 (2010).
-
(2010)
Invest. New Drugs
, vol.28
, pp. 49-60
-
-
Seidl, C.1
Port, M.2
Apostolidis, C.3
-
28
-
-
84875849377
-
Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation
-
Danielsson A, Claesson K, Parris TZ et al. Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation. Int. J. Radiat. Biol. 89, 250-258 (2013).
-
(2013)
Int. J. Radiat. Biol.
, vol.89
, pp. 250-258
-
-
Danielsson, A.1
Claesson, K.2
Parris, T.Z.3
-
29
-
-
84865620494
-
Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: The molecular choreography
-
Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat. Res. 751, 158-246 (2012).
-
(2012)
Mutat. Res.
, vol.751
, pp. 158-246
-
-
Thompson, L.H.1
-
30
-
-
84873350765
-
Molecular pathways: Targeted α-particle radiation therapy
-
Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clin. Cancer Res. 19, 530-537 (2013).
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 530-537
-
-
Baidoo, K.E.1
Yong, K.2
Brechbiel, M.W.3
-
31
-
-
80052209707
-
Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates
-
Dahle J, Abbas N, Bruland ?S, Larsen RH. Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates. Curr. Radiopharm. 4, 321-328 (2011).
-
(2011)
Curr. Radiopharm.
, vol.4
, pp. 321-328
-
-
Dahle, J.1
Abbas, N.2
Bruland, S.3
Larsen, R.H.4
-
33
-
-
0037464557
-
Experimental detection of α-particles from the radioactive decay of natural bismuth
-
DOI 10.1038/nature01541
-
de Marcillac P, Coron N, Dambier G, Leblanc J, Moalic JP. Experimental detection of alpha-particles from the radioactive decay of natural bismuth. Nature 422, 876-878 (2003). (Pubitemid 36520036)
-
(2003)
Nature
, vol.422
, Issue.6934
, pp. 876-878
-
-
De Marcillac, P.1
Coron, N.2
Dambier, G.3
Leblanc, J.4
Moalic, J.-P.5
-
34
-
-
26444597027
-
Production of Ac-225 from Th-229 for targeted α therapy
-
DOI 10.1021/ac0580114
-
Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal. Chem. 77, 6288-6291(2005). (Pubitemid 41436964)
-
(2005)
Analytical Chemistry
, vol.77
, Issue.19
, pp. 6288-6291
-
-
Apostolidis, C.1
Molinet, R.2
Rasmussen, G.3
Morgenstern, A.4
-
35
-
-
84863557811
-
Bismuth-213 and actinium-225-generator performance and evolving therapeutic applications of two generator-derived alphaemitting radioisotopes
-
Morgenstern A, Bruchertseifer F, Apostolidis C. Bismuth-213 and actinium-225-generator performance and evolving therapeutic applications of two generator-derived alphaemitting radioisotopes. Curr. Radiopharm. 5, 221-227 (2012).
-
(2012)
Curr. Radiopharm.
, vol.5
, pp. 221-227
-
-
Morgenstern, A.1
Bruchertseifer, F.2
Apostolidis, C.3
-
36
-
-
79551705078
-
Renal ptauke of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
-
Schwartz J, Jaggi JS, O'Donoghue JA et al. Renal ptauke of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys. Med. Biol. 56, 721-733 (2011).
-
(2011)
Phys. Med. Biol.
, vol.56
, pp. 721-733
-
-
Schwartz, J.1
Jaggi, J.S.2
O'Donoghue, J.A.3
-
37
-
-
45749101319
-
225Ac in rigid liposomes for potential targeted therapy of micrometastases
-
DOI 10.1021/bc700440a
-
Chang MY, Seideman J, Sofou S. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjug. Chem. 19, 1274-1282 (2008). (Pubitemid 351874951)
-
(2008)
Bioconjugate Chemistry
, vol.19
, Issue.6
, pp. 1274-1282
-
-
Change, M.-Y.1
Seideman, J.2
Sofou, S.3
-
38
-
-
84872565992
-
Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy
-
McLaughlin MF, Woodward J, Boll RA et al. Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. PLoS ONE 8, e54531 (2013).
-
(2013)
PLoS ONE
, vol.8
-
-
McLaughlin, M.F.1
Woodward, J.2
Boll, R.A.3
-
39
-
-
79959430516
-
Astatine-211: Production and availability
-
Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr. Radiopharm. 4, 177-185 (2011).
-
(2011)
Curr. Radiopharm.
, vol.4
, pp. 177-185
-
-
Zalutsky, M.R.1
Pruszynski, M.2
-
40
-
-
84872176323
-
Production of [211) At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy
-
Gu?ard F, Gestin JF, Brechbiel MW. Production of [(211) At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. Cancer Biother. Radiopharm. 28, 1-20 (2013).
-
(2013)
Cancer Biother. Radiopharm
, vol.28
, pp. 1-20
-
-
Guard, F.1
Gestin, J.F.2
Brechbiel, M.W.3
-
42
-
-
0001042459
-
2 fragments with the α-particle-emitting nuclide astatine-211: Preservation of immunoreactivity and in vivo localizing capacity
-
Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc. Natl Acad. Sci. USA 86, 7149-7153 (1989). (Pubitemid 19240882)
-
(1989)
Proceedings of the National Academy of Sciences of the United States of America
, vol.86
, Issue.18
, pp. 7149-7153
-
-
Zalutsky, M.R.1
Garg, P.K.2
Friedman, H.S.3
Bigner, D.D.4
-
43
-
-
84863382114
-
Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with A maleimido-closo-decaborate(2-) Reagent Via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations Than the Same Antibody Conjugated with An Isothiocyanato-closodecaborate( 2-) Reagent Via Lysine Amines
-
Wilbur DS, Chyan MK, Nakamae H et al. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo- decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato- closodecaborate( 2-) reagent via lysine amines. Bioconjug. Chem. 23, 409-420 (2012).
-
(2012)
Bioconjug. Chem.
, vol.23
, pp. 409-420
-
-
Wilbur, D.S.1
Chyan, M.K.2
Nakamae, H.3
-
44
-
-
79958212847
-
Towards translation of 212Pb as a clinical therapeutic; Getting the lead
-
Yong K, Brechbiel MW. Towards translation of 212Pb as a clinical therapeutic; getting the lead in! Dalton Trans. 40, 6068-6076 (2011).
-
(2011)
Dalton Trans
, vol.40
, pp. 6068-6076
-
-
Yong, K.1
Brechbiel, M.W.2
-
45
-
-
84878174664
-
Methodology for labeling proteins and peptides with lead-212 (212Pb)
-
Baidoo KE, Milenic DE, Brechbiel MW. Methodology for labeling proteins and peptides with lead-212 (212Pb). Nucl. Med. Biol. 40, 592-599 (2013).
-
(2013)
Nucl. Med. Biol.
, vol.40
, pp. 592-599
-
-
Baidoo, K.E.1
Milenic, D.E.2
Brechbiel, M.W.3
-
46
-
-
84891676245
-
Half-lifes of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series
-
Suliman G, Pomm?S, Marouli M et al. Half-lifes of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series. Appl. Radiat. Isot. 77, 32-37 (2013).
-
(2013)
Appl. Radiat. Isot.
, vol.77
, pp. 32-37
-
-
Suliman, G.1
Pomms2
Marouli, M.3
-
47
-
-
1842850605
-
Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides
-
DOI 10.1016/j.nucmedbio.2003.11.004, PII S0969805103002117
-
Henriksen G, Schoultz BW, Michaelsen TE, Bruland ?S, Larsen RH. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl. Med. Biol. 31, 441-449 (2004). (Pubitemid 38490743)
-
(2004)
Nuclear Medicine and Biology
, vol.31
, Issue.4
, pp. 441-449
-
-
Henriksen, G.1
Schoultz, B.W.2
Michaelsen, T.E.3
Bruland, O.S.4
Larsen, R.H.5
-
48
-
-
84881630281
-
Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castrationresistant metastatic prostate cancer
-
Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castrationresistant metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 40, 1384-1393 (2013).
-
(2013)
Eur. J. Nucl. Med. Mol. Imaging
, vol.40
, pp. 1384-1393
-
-
Carrasquillo, J.A.1
O'Donoghue, J.A.2
Pandit-Taskar, N.3
-
49
-
-
84872507131
-
Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
-
Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag. Res. 5, 1-14 (2013).
-
(2013)
Cancer Manag. Res.
, vol.5
, pp. 1-14
-
-
Harrison, M.R.1
Wong, T.Z.2
Armstrong, A.J.3
George, D.J.4
-
50
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213-223 (2013).
-
(2013)
N. Engl. J. Med.
, vol.369
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
51
-
-
0037964241
-
Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-Cadherin adhesion protein
-
DOI 10.1667/0033-7587(2003)159[0612:COTROT]2.0.CO;2
-
Miederer M, Seidl C, Beyer GJ et al. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein. Radiat. Res. 159, 612-620 (2003). (Pubitemid 36539240)
-
(2003)
Radiation Research
, vol.159
, Issue.5
, pp. 612-620
-
-
Miederer, M.1
Seidl, C.2
Beyer, G.-J.3
Charlton, D.E.4
Vranjes-Duric, S.5
Comor, J.J.6
Huber, R.7
Nikula, T.8
Apostolidis, C.9
Schuhmacher, C.10
Becker, K.-F.11
Senekowitsch-Schmidtke, R.12
-
52
-
-
84864121928
-
Measurement of the 226Th and 222Ra half-lives
-
Pomm?S, Suliman G, Marouli M et al. Measurement of the 226Th and 222Ra half-lives. Appl. Radiat. Isot. 70, 1913-1918 (2012).
-
(2012)
Appl. Radiat. Isot.
, vol.70
, pp. 1913-1918
-
-
Pomm, S.1
Suliman, G.2
Marouli, M.3
-
54
-
-
56449102606
-
Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa
-
Morgenstern A, Lebeda O, Stursa J et al. Production of 230U/226Th for targeted alpha therapy via proton irradiation of 231Pa. Anal. Chem. 80, 8763-8770 (2008).
-
(2008)
Anal. Chem.
, vol.80
, pp. 8763-8770
-
-
Morgenstern, A.1
Lebeda, O.2
Stursa, J.3
-
55
-
-
84900427069
-
Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAb
-
Toronto, Canada,13-17 June
-
Pfost B, Morgenstern A, Seidl C et al. Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAb. Presented at: the 6th Symposium on Alpha-Emitting Radionuclides in Therapy. Toronto, Canada, 13-17 June 2009.
-
(2009)
6th Symposium on Alpha-Emitting Radionuclides in Therapy
-
-
Pfost, B.1
Morgenstern, A.2
Seidl, C.3
-
56
-
-
33644942120
-
Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate alphaparticle radioimmunotherapy
-
Dahle J, Borrebaek J, Melhus KB et al. Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate alphaparticle radioimmunotherapy. Nucl. Med. Biol. 33, 271-279 (2006).
-
(2006)
Nucl. Med. Biol.
, vol.33
, pp. 271-279
-
-
Dahle, J.1
Borrebaek, J.2
Melhus, K.B.3
-
57
-
-
34447525352
-
227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability
-
DOI 10.1089/cbr.2006.321
-
Larsen RH, Borrebaek J, Dahle J et al. Preparation of 227Th-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability. Cancer Biother. Radiopharm. 22, 431-437 (2007). (Pubitemid 47067902)
-
(2007)
Cancer Biotherapy and Radiopharmaceuticals
, vol.22
, Issue.3
, pp. 431-437
-
-
Larsen, R.H.1
Borrebaek, J.2
Dahle, J.3
Melhus, K.B.4
Krogh, C.5
Valan, M.H.6
Bruland, O.S.7
-
58
-
-
80052230219
-
Actinium-225 in targeted alpha-particle therapeutic applications
-
Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr. Radiopharm. 4, 306-320 (2011).
-
(2011)
Curr. Radiopharm.
, vol.4
, pp. 306-320
-
-
Scheinberg, D.A.1
McDevitt, M.R.2
-
59
-
-
0035900395
-
Tumor therapy with targeted atomic nanogenerators
-
DOI 10.1126/science.1064126
-
McDevitt MR, Ma D, Lai LT et al. Tumor therapy with targeted atomic nanogenerators. Science 294, 1537-1540 (2001). (Pubitemid 33063927)
-
(2001)
Science
, vol.294
, Issue.5546
, pp. 1537-1540
-
-
McDevitt, M.R.1
Ma, D.2
Lai, L.T.3
Simon, J.4
Borchardt, P.5
Frank, R.K.6
Wu, K.7
Pellegrini, V.8
Curcio, M.J.9
Miederer, M.10
Bander, N.H.11
Scheinberg, D.A.12
-
60
-
-
0041513403
-
Targeted actinium-225 in vivo generators for therapy of ovarian cancer
-
Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 63, 5084-5090 (2003). (Pubitemid 37022648)
-
(2003)
Cancer Research
, vol.63
, Issue.16
, pp. 5084-5090
-
-
Borchardt, P.E.1
Yuan, R.R.2
Miederer, M.3
McDevitt, M.R.4
Scheinberg, D.A.5
-
61
-
-
6044248953
-
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of α-emitting atomic nanogenerators targeting disialo-ganglioside GD2
-
DOI 10.1158/1078-0432.CCR-04-0859
-
Miederer M, McDevitt MR, Borchardt P et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin. Cancer Res. 10, 6985-6992 (2004). (Pubitemid 39383050)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.20
, pp. 6985-6992
-
-
Miederer, M.1
McDevitt, M.R.2
Borchardt, P.3
Bergman, I.4
Kramer, K.5
Cheung, N.-K.V.6
Scheinberg, D.A.7
-
62
-
-
84891702990
-
Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization
-
Jaggi JS, Henke E, Seshan SV et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS ONE 2, e267 (2007).
-
(2007)
PLoS ONE
, vol.2
-
-
Jaggi, J.S.1
Henke, E.2
Seshan, S.V.3
-
63
-
-
78549248213
-
Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors
-
Escorcia FE, Henke E, McDevitt MR et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res. 70, 9277-9286 (2010).
-
(2010)
Cancer Res.
, vol.70
, pp. 9277-9286
-
-
Escorcia, F.E.1
Henke, E.2
McDevitt, M.R.3
-
64
-
-
79952115407
-
Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes
-
Ruggiero A, Villa CH, Holland JP et al. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int. J. Nanomedicine 5, 783-802 (2010).
-
(2010)
Int. J. Nanomedicine
, vol.5
, pp. 783-802
-
-
Ruggiero, A.1
Villa, C.H.2
Holland, J.P.3
-
65
-
-
77955459129
-
Paradoxical glomerular filtration of carbon nanotubes
-
Ruggiero A, Villa CH, Bander E et al. Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl Acad. Sci. USA 107, 12369-12374 (2010).
-
(2010)
Proc. Natl Acad. Sci. USA
, vol.107
, pp. 12369-12374
-
-
Ruggiero, A.1
Villa, C.H.2
Bander, E.3
-
66
-
-
71549168624
-
Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac comparing efficacy with 213Bi and 90Y
-
Song H, Hobbs RF, Vajravelu R et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac. comparing efficacy with 213Bi and 90Y. Cancer Res. 69, 8941-8948 (2009).
-
(2009)
Cancer Res.
, vol.69
, pp. 8941-8948
-
-
Song, H.1
Hobbs, R.F.2
Vajravelu, R.3
-
67
-
-
34848890264
-
211At-labeled monoclonal antibodies
-
DOI 10.1016/j.nucmedbio.2007.03.007, PII S0969805107000911
-
Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211Atlabeled monoclonal antibodies. Nucl. Med. Biol. 34, 779-785 (2007). (Pubitemid 47505399)
-
(2007)
Nuclear Medicine and Biology
, vol.34
, Issue.7
, pp. 779-785
-
-
Zalutsky, M.R.1
Reardon, D.A.2
Pozzi, O.R.3
Vaidyanathan, G.4
Bigner, D.D.5
-
68
-
-
80052242015
-
Applications of 211At and 223Ra in targeted alpha-particle radiotherapy
-
Vaidyanathan G, Zalutsky MR. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. Curr. Radiopharm. 4, 283-294 (2011).
-
(2011)
Curr. Radiopharm.
, vol.4
, pp. 283-294
-
-
Vaidyanathan, G.1
Zalutsky, M.R.2
-
69
-
-
27744551829
-
211At-labeled antibody A33 - A potential therapeutic agent against metastatic colorectal carcinoma
-
DOI 10.1089/cbr.2005.20.514
-
Almqvist Y, Orlova A, Sj?tr? A et al. In vitro characterization of 211At-labeled antibody A33-a potential therapeutic agent against metastatic colorectal carcinoma. Cancer Biother. Radiopharm. 20, 514-523 (2005). (Pubitemid 41619143)
-
(2005)
Cancer Biotherapy and Radiopharmaceuticals
, vol.20
, Issue.5
, pp. 514-523
-
-
Almqvist, Y.1
Orlova, A.2
Sjostrom, A.3
Jensen, H.J.4
Lundqvist, H.5
Sundin, A.6
Tolmachev, V.7
-
70
-
-
33646061955
-
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity on survival fraction
-
Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl. Med. Biol. 33, 333-347 (2006).
-
(2006)
Nucl. Med. Biol.
, vol.33
, pp. 333-347
-
-
Akabani, G.1
Carlin, S.2
Welsh, P.3
Zalutsky, M.R.4
-
71
-
-
84864066701
-
Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with 211At
-
Cederkrantz E, Angenete E, B?k T et al. Evaluation of effects on the peritoneum after intraperitoneal α-radioimmunotherapy with 211At. Cancer Biother. Radiopharm. 27, 353-364 (2012).
-
(2012)
Cancer Biother. Radiopharm.
, vol.27
, pp. 353-364
-
-
Cederkrantz, E.1
Angenete, E.2
Bk, T.3
-
72
-
-
67651177582
-
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting 211At-labeled trastuzumab
-
Boskovitz A, McLendon RE, Okamura T, Sampson JH, Bigner DD, Zalutsky MR. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting 211At-labeled trastuzumab. Nucl. Med. Biol. 36, 659-669 (2009).
-
(2009)
Nucl. Med. Biol.
, vol.36
, pp. 659-669
-
-
Boskovitz, A.1
McLendon, R.E.2
Okamura, T.3
Sampson, J.H.4
Bigner, D.D.5
Zalutsky, M.R.6
-
73
-
-
38949203047
-
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the α-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies
-
DOI 10.1158/1078-0432.CCR-07-1250
-
Robinson MK, Shaller C, Garmestani K et al. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alphaemitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin. Cancer Res. 14, 875-882 (2008). (Pubitemid 351231172)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.3
, pp. 875-882
-
-
Robinson, M.K.1
Shaller, C.2
Garmestani, K.3
Plascjak, P.S.4
Hodge, K.M.5
Yuan, Q.-A.6
Marks, J.D.7
Waldmann, T.A.8
Brechbiel, M.W.9
Adams, G.P.10
-
74
-
-
34249889331
-
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma
-
DOI 10.1097/MLG.0b013e31804b1a6d
-
Cheng J, Ekberg T, Engstr? M et al. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. Laryngoscope 117, 1013-1018 (2007). (Pubitemid 46869837)
-
(2007)
Laryngoscope
, vol.117
, Issue.6
, pp. 1013-1018
-
-
Cheng, J.1
Ekberg, T.2
Engstrom, M.3
Nestor, M.4
Jensen, H.J.5
Tolmachev, V.6
Anniko, M.7
-
75
-
-
33748045787
-
211At, provides effective radioimmunotherapy for a murine model of leukemia
-
DOI 10.1158/0008-5472.CAN-06-1189
-
Zhang M, Yao Z, Zhang Z et al. The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res. 66, 8227-8232 (2006). (Pubitemid 44299191)
-
(2006)
Cancer Research
, vol.66
, Issue.16
, pp. 8227-8232
-
-
Zhang, M.1
Yao, Z.2
Zhang, Z.3
Garmestani, K.4
Talanov, V.S.5
Plascjak, P.S.6
Yu, S.7
Kim, H.-S.8
Goldman, C.K.9
Paik, C.H.10
Brechbiel, M.W.11
Carrasquillo, J.A.12
Waldmann, T.A.13
-
76
-
-
33746644134
-
211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25
-
DOI 10.1182/blood-2005-11-4757
-
Zhang Z, Zhang M, Garmestani K et al. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood 108, 1007-1012 (2006). (Pubitemid 44154638)
-
(2006)
Blood
, vol.108
, Issue.3
, pp. 1007-1012
-
-
Zhang, Z.1
Zhang, M.2
Garmestani, K.3
Talanov, V.S.4
Plascjak, P.S.5
Beck, B.6
Goldman, C.7
Brechbiel, M.W.8
Waldmann, T.A.9
-
77
-
-
34347256772
-
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
-
DOI 10.1073/pnas.0702496104
-
Zhang M, Yao Z, Patel H et al. Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1. Proc. Natl Acad. Sci. USA 104, 8444-8448 (2007). (Pubitemid 47175507)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.20
, pp. 8444-8448
-
-
Zhang, M.1
Yao, Z.2
Patel, H.3
Garmestani, K.4
Zhang, Z.5
Talanov, V.S.6
Plascjak, P.S.7
Goldman, C.K.8
Janik, J.E.9
Brechbiel, M.W.10
Waldmann, T.A.11
-
78
-
-
34548478370
-
Therapeutic Efficacy of Astatine-211-Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice
-
DOI 10.1016/j.ijrobp.2007.06.023, PII S036030160701142X
-
Palm S, B?k T, Claesson I et al. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int. J. Radiat. Oncol. Biol. Phys. 69, 572-579 (2007). (Pubitemid 47380120)
-
(2007)
International Journal of Radiation Oncology Biology Physics
, vol.69
, Issue.2
, pp. 572-579
-
-
Palm, S.1
Back, T.2
Claesson, I.3
Danielsson, A.4
Elgqvist, J.5
Frost, S.6
Hultborn, R.7
Jensen, H.8
Lindegren, S.9
Jacobsson, L.10
-
79
-
-
33644832911
-
211at- labeled monoclonal antibody MX35
-
Elgqvist J, Andersson H, B?k T et al. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with 211At-labeled monoclonal antibody MX35. J. Nucl. Med. 46, 1907-1915 (2005). (Pubitemid 46196654)
-
(2005)
Journal of Nuclear Medicine
, vol.46
, Issue.11
, pp. 1907-1915
-
-
Elgqvist, J.1
Andersson, H.2
Back, T.3
Hultborn, R.4
Jensen, H.5
Karlsson, B.6
Lindegren, S.7
Palm, S.8
Warnhammar, E.9
Jacobsson, L.10
-
80
-
-
33644878034
-
211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an α-emitter in vivo
-
B?k T, Andersson H, Divgi CR et al. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts. evaluation of relative biologic effectiveness of an alpha-emitter in vivo. J. Nucl. Med. 46, 2061-2067 (2005). (Pubitemid 46657454)
-
(2005)
Journal of Nuclear Medicine
, vol.46
, Issue.12
, pp. 2061-2067
-
-
Back, T.1
Andersson, H.2
Divgi, C.R.3
Hultborn, R.4
Jensen, H.5
Lindegren, S.6
Palm, S.7
Jacobsson, L.8
-
81
-
-
79959191869
-
Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer in mice
-
Elgqvist J, Andersson H, Jensen H et al. Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer in mice. J. Oncol. 2010, 394913 (2010).
-
(2010)
J. Oncol.
, vol.2010
, pp. 394913
-
-
Elgqvist, J.1
Andersson, H.2
Jensen, H.3
-
82
-
-
33749043460
-
α-Radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose
-
Elgqvist J, Andersson H, B?k T et al. Alpharadioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions. Outcome related to measured tumor size and mean absorbed dose. J. Nucl. Med. 47, 1342-1350 (2006). (Pubitemid 47544890)
-
(2006)
Journal of Nuclear Medicine
, vol.47
, Issue.8
, pp. 1342-1350
-
-
Elgqvist, J.1
Andersson, H.2
Back, T.3
Claesson, I.4
Hultborn, R.5
Jensen, H.6
Johansson, B.R.7
Lindegren, S.8
Olsson, M.9
Palm, S.10
Warnhammar, E.11
Jacobsson, L.12
-
83
-
-
69249107784
-
Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities
-
Elgqvist J, Andersson H, Haglund E et al. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother. Radiopharm. 24, 509-513 (2009).
-
(2009)
Cancer Biother. Radiopharm.
, vol.24
, pp. 509-513
-
-
Elgqvist, J.1
Andersson, H.2
Haglund, E.3
-
84
-
-
84855322802
-
Comparison of therapeutic efficacy and biodistribution of 213Bi-and 211Atlabeled monoclonal antibody MX35 in an ovarian cancer model
-
Gustafsson AM, B?k T, Elgqvist J et al. Comparison of therapeutic efficacy and biodistribution of 213Bi-and 211Atlabeled monoclonal antibody MX35 in an ovarian cancer model. Nucl. Med. Biol. 39, 15-22 (2012).
-
(2012)
Nucl. Med. Biol.
, vol.39
, pp. 15-22
-
-
Gustafsson, A.M.1
Bk, T.2
Elgqvist, J.3
-
85
-
-
84874755179
-
Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model
-
Frost SH, B?k T, Chouin N et al. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother. Radiopharm. 28, 108-114 (2013).
-
(2013)
Cancer Biother. Radiopharm.
, vol.28
, pp. 108-114
-
-
Frost, S.H.1
Bk, T.2
Chouin, N.3
-
86
-
-
84881422571
-
Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique
-
Chouin N, Lindegren S, Frost SH et al. Ex vivo activity quantification in micrometastases at the cellular scale using the α-camera technique. J. Nucl. Med. 54, 1347-1353 (2013).
-
(2013)
J. Nucl. Med.
, vol.54
, pp. 1347-1353
-
-
Chouin, N.1
Lindegren, S.2
Frost, S.H.3
-
87
-
-
84863012882
-
Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation
-
Chen Y, Kornblit B, Hamlin DK et al. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 119, 1130-1138 (2012).
-
(2012)
Blood
, vol.119
, pp. 1130-1138
-
-
Chen, Y.1
Kornblit, B.2
Hamlin, D.K.3
-
88
-
-
84879712790
-
Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
-
Orozco JJ, B?k T, Kenoyer A et al. Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood 121, 3759-3767 (2013).
-
(2013)
Blood
, vol.121
, pp. 3759-3767
-
-
Orozco, J.J.1
Bk, T.2
Kenoyer, A.3
-
89
-
-
84876850544
-
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb
-
Eriksson SE, B?k T, Elgstr? E et al. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb. EJNMMI Res. 3, 23 (2013).
-
(2013)
EJNMMI Res.
, vol.3
, pp. 23
-
-
Eriksson, S.E.1
Bk, T.2
Elgstr, E.3
-
90
-
-
0011736580
-
Bismuth-212-labeled anti-Tac monoclonal antibody: α-Particle- emitting radionuclides as modalities for radioimmunotherapy
-
Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl Acad. Sci. USA 83, 474-478 (1986). (Pubitemid 16080036)
-
(1986)
Proceedings of the National Academy of Sciences of the United States of America
, vol.83
, Issue.2
, pp. 474-478
-
-
Kozak, R.W.1
Atcher, R.W.2
Gansow, O.A.3
-
91
-
-
79959556136
-
Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides
-
Wilbur DS. Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides. Curr. Radiopharm. 4, 214-247 (2011).
-
(2011)
Curr. Radiopharm.
, vol.4
, pp. 214-247
-
-
Wilbur, D.S.1
-
92
-
-
84878194238
-
Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies
-
Kang CS, Song HA, Milenic DE, Baidoo KE, Brechbiel MW, Chong HS. Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies. Nucl. Med. Biol. 40, 600-605 (2013).
-
(2013)
Nucl. Med. Biol.
, vol.40
, pp. 600-605
-
-
Kang, C.S.1
Song, H.A.2
Milenic, D.E.3
Baidoo, K.E.4
Brechbiel, M.W.5
Chong, H.S.6
-
93
-
-
0026737729
-
Effective alpha-particle-mediated radioimmunotherapy of murine leukemia
-
Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 52, 5818-5820 (1992).
-
(1992)
Cancer Res.
, vol.52
, pp. 5818-5820
-
-
Huneke, R.B.1
Pippin, C.G.2
Squire, R.A.3
Brechbiel, M.W.4
Gansow, O.A.5
Strand, M.6
-
94
-
-
0028070359
-
Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac
-
Hartmann F, Horak EM, Garmestani K et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res. 54, 4362-4370 (1994).
-
(1994)
Cancer Res.
, vol.54
, pp. 4362-4370
-
-
Hartmann, F.1
Horak, E.M.2
Garmestani, K.3
-
95
-
-
12144290050
-
211At
-
DOI 10.1016/j.nucmedbio.2003.08.011, PII S0969805103001628
-
Wesley JN, McGee EC, Garmestani K et al. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides 212Bi or 211At. Nucl. Med. Biol. 31, 357-364 (2004). (Pubitemid 38353031)
-
(2004)
Nuclear Medicine and Biology
, vol.31
, Issue.3
, pp. 357-364
-
-
Wesley, J.N.1
McGee, E.C.2
Garmestani, K.3
Brechbiel, M.W.4
Yordanov, A.T.5
Wu, C.6
Gansow, O.A.7
Eckelman, W.C.8
Bacher, J.D.9
Flynn, M.10
Goldman, C.K.11
MacLin, M.12
Schwartz, U.P.13
Jackson-White, T.14
Phillip, C.M.15
Decker, J.16
Waldmann, T.A.17
-
96
-
-
27744567367
-
212Pb-labeled radioimmunoconjugate targeting HER2
-
DOI 10.1089/cbr.2005.20.557
-
Milenic DE, Garmestani K, Brady ED et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother. Radiopharm. 20, 557-568 (2005). (Pubitemid 41619147)
-
(2005)
Cancer Biotherapy and Radiopharmaceuticals
, vol.20
, Issue.5
, pp. 557-568
-
-
Milenic, D.E.1
Garmestani, K.2
Brady, E.D.3
Albert, P.S.4
Ma, D.5
Abdulla, A.6
Brechbiel, M.W.7
-
97
-
-
84859386203
-
212Pbradioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease
-
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 212Pbradioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol. Cancer Ther. 11, 639-648 (2012).
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 639-648
-
-
Yong, K.J.1
Milenic, D.E.2
Baidoo, K.E.3
Brechbiel, M.W.4
-
98
-
-
34250217093
-
Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease
-
DOI 10.1158/1078-0432.CCR-06-2300
-
Milenic DE, Garmestani K, Brady ED et al. Potentiation of high-LET radiation by gemcitabine. targeting HER2 with trastuzumab to treat disseminated peritoneal disease. Clin. Cancer Res. 13, 1926-1935 (2007). (Pubitemid 46957364)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.6
, pp. 1926-1935
-
-
Milenic, D.E.1
Garmestani, K.2
Brady, E.D.3
Albert, P.S.4
Abdulla, A.5
Flynn, J.6
Brechbiel, M.W.7
-
99
-
-
52649160241
-
Multimodality therapy potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease
-
Milenic DE, Garmestani K, Brady ED et al. Multimodality therapy. potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 14, 5108-5115 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 5108-5115
-
-
Milenic, D.E.1
Garmestani, K.2
Brady, E.D.3
-
100
-
-
84875214677
-
Sensitization of tumor to 212Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51
-
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Sensitization of tumor to 212Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. Int. J. Radiat. Oncol. Biol. Phys. 85, 1119-1126 (2013).
-
(2013)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.85
, pp. 1119-1126
-
-
Yong, K.J.1
Milenic, D.E.2
Baidoo, K.E.3
Brechbiel, M.W.4
-
101
-
-
84878550840
-
212Pbradioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
-
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 212Pbradioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint. Br. J. Cancer 108, 2013-2020 (2013).
-
(2013)
Br. J. Cancer
, vol.108
, pp. 2013-2020
-
-
Yong, K.J.1
Milenic, D.E.2
Baidoo, K.E.3
Brechbiel, M.W.4
-
102
-
-
84880785330
-
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb
-
Boudousq V, Bobyk L, Busson M et al. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS ONE 8, e69613 (2013).
-
(2013)
PLoS ONE
, vol.8
-
-
Boudousq, V.1
Bobyk, L.2
Busson, M.3
-
103
-
-
16444385850
-
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro
-
DOI 10.1089/cbr.2005.20.52
-
Nayak T, Norenberg J, Anderson T, Atcher R. A comparison of high-versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother. Radiopharm. 20, 52-57 (2005). (Pubitemid 40478522)
-
(2005)
Cancer Biotherapy and Radiopharmaceuticals
, vol.20
, Issue.1
, pp. 52-57
-
-
Nayak, T.1
Norenberg, J.2
Anderson, T.3
Atcher, R.4
-
104
-
-
84875792991
-
Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio-and chemoresistant non-Hodgkin lymphoma cells
-
Roscher M, Hormann I, Leib O et al. Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio-and chemoresistant non-Hodgkin lymphoma cells. Oncotarget 4, 218-230 (2013).
-
(2013)
Oncotarget
, vol.4
, pp. 218-230
-
-
Roscher, M.1
Hormann, I.2
Leib, O.3
-
105
-
-
84879320732
-
Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio-and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large
-
doi:10.1016/j.ejca.2013.04.008 Epub ahead of print
-
Friesen C, Roscher M, Hormann I et al. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio-and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large. Eur. J. Cancer doi:10.1016/j.ejca.2013. 04.008 (2013) (Epub ahead of print).
-
(2013)
Eur. J. Cancer
-
-
Friesen, C.1
Roscher, M.2
Hormann, I.3
-
106
-
-
84866160432
-
Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells
-
Haro KJ, Scott AC, Scheinberg DA. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood 120, 2087-2097 (2012).
-
(2012)
Blood
, vol.120
, pp. 2087-2097
-
-
Haro, K.J.1
Scott, A.C.2
Scheinberg, D.A.3
-
107
-
-
68149132396
-
Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic mice
-
Allen BJ, So T, Abbas Rizvi SM, Song EY, Fernandez HR, Lutz-Mann L. Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic mice. Cancer Biol. Ther. 8, 777-781 (2009).
-
(2009)
Cancer Biol. Ther.
, vol.8
, pp. 777-781
-
-
Allen, B.J.1
So, T.2
Abbas Rizvi, S.M.3
Song, E.Y.4
Fernandez, H.R.5
Lutz-Mann, L.6
-
108
-
-
33845316055
-
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins
-
Dadachova E, Patel MC, Toussi S et al. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med. 3, e427 (2006).
-
(2006)
PLoS Med.
, vol.3
-
-
Dadachova, E.1
Patel, M.C.2
Toussi, S.3
-
109
-
-
84857952424
-
Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication
-
Dadachova E, Kitchen SG, Bristol G et al. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS ONE 7, e31866 (2012).
-
(2012)
PLoS ONE
, vol.7
-
-
Dadachova, E.1
Kitchen, S.G.2
Bristol, G.3
-
110
-
-
70350328006
-
Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax
-
Rivera J, Nakouzi AS, Morgenstern A, Bruchertseifer F, Dadachova E, Casadevall A. Radiolabeled antibodies to Bacillus anthracis toxins are bactericidal and partially therapeutic in experimental murine anthrax. Antimicrob. Agents Chemother. 53, 4860-4868 (2009).
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 4860-4868
-
-
Rivera, J.1
Nakouzi, A.S.2
Morgenstern, A.3
Bruchertseifer, F.4
Dadachova, E.5
Casadevall, A.6
-
111
-
-
65649121945
-
Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells
-
Bryan RA, Jiang Z, Huang X et al. Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells. Antimicrob. Agents Chemother. 53, 1679-1682 (2009).
-
(2009)
Antimicrob. Agents Chemother.
, vol.53
, pp. 1679-1682
-
-
Bryan, R.A.1
Jiang, Z.2
Huang, X.3
-
112
-
-
77954690760
-
Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection
-
Bryan RA, Jiang Z, Howell RC et al. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J. Infect. Dis. 202, 633-637 (2010).
-
(2010)
J. Infect. Dis.
, vol.202
, pp. 633-637
-
-
Bryan, R.A.1
Jiang, Z.2
Howell, R.C.3
-
113
-
-
84455161653
-
Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice
-
Jiang Z, Bryan RA, Morgenstern A, Bruchertseifer F, Casadevall A, Dadachova E. Treatment of early and established Cryptococcus neoformans infection with radiolabeled antibodies in immunocompetent mice. Antimicrob. Agents Chemother. 56, 552-554 (2012).
-
(2012)
Antimicrob. Agents Chemother.
, vol.56
, pp. 552-554
-
-
Jiang, Z.1
Bryan, R.A.2
Morgenstern, A.3
Bruchertseifer, F.4
Casadevall, A.5
Dadachova, E.6
-
114
-
-
84860586440
-
Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens
-
Bryan RA, Guimaraes AJ, Hopcraft S et al. Toward developing a universal treatment for fungal disease using radioimmunotherapy targeting common fungal antigens. Mycopathologia 173, 463-471 (2012).
-
(2012)
Mycopathologia
, vol.173
, pp. 463-471
-
-
Bryan, R.A.1
Guimaraes, A.J.2
Hopcraft, S.3
-
115
-
-
0036660169
-
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts
-
DOI 10.1182/blood-2001-12-0322
-
Sandmaier BM, Bethge WA, Wilbur DS et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 100, 318-326 (2002). (Pubitemid 35177463)
-
(2002)
Blood
, vol.100
, Issue.1
, pp. 318-326
-
-
Sandmaier, B.M.1
Bethge, W.A.2
Scott Wilbur, D.3
Hamlin, D.K.4
Santos, E.B.5
Brechbiel, M.W.6
Fisher, D.R.7
Storb, R.8
-
116
-
-
77953330556
-
Pilot study of a 213bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation
-
Nakamae H, Kerbauy FR, Wilbur DS et al. Pilot study of a 213bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation. Transplantation 89, 1336-1340 (2010).
-
(2010)
Transplantation
, vol.89
, pp. 1336-1340
-
-
Nakamae, H.1
Kerbauy, F.R.2
Wilbur, D.S.3
-
117
-
-
65549097348
-
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211
-
Nakamae H, Wilbur DS, Hamlin DK et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 69, 2408-2415 (2009).
-
(2009)
Cancer Res.
, vol.69
, pp. 2408-2415
-
-
Nakamae, H.1
Wilbur, D.S.2
Hamlin, D.K.3
-
118
-
-
0038044865
-
Selective T-cell ablation with bismuth-213-labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation
-
Bethge WA, Wilbur DS, Storb R et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 101, 5068-5075 (2003). (Pubitemid 36857775)
-
(2003)
Blood
, vol.101
, Issue.12
, pp. 5068-5075
-
-
Bethge, W.A.1
Wilbur, D.S.2
Storb, R.3
Hamlin, D.K.4
Santos, E.B.5
Brechbiel, M.W.6
Fisher, D.R.7
Sandmaier, B.M.8
-
119
-
-
79960684246
-
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213 high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
-
Pagel JM, Kenoyer AL, B?k T et al. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213. high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood 118, 703-711 (2011).
-
(2011)
Blood
, vol.118
, pp. 703-711
-
-
Pagel, J.M.1
Kenoyer, A.L.2
Bk, T.3
-
120
-
-
78549263790
-
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: A preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
-
Park SI, Shenoi J, Pagel JM et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood 116, 4231-4239 (2010).
-
(2010)
Blood
, vol.116
, pp. 4231-4239
-
-
Park, S.I.1
Shenoi, J.2
Pagel, J.M.3
-
121
-
-
0037452667
-
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
-
DOI 10.1073/pnas.0437788100
-
Zhang M, Zhang Z, Garmestani K et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl Acad. Sci. USA 100, 1891-1895 (2003). (Pubitemid 36254544)
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.4
, pp. 1891-1895
-
-
Zhang, M.1
Zhang, Z.2
Garmestani, K.3
Schultz, J.4
Axworthy, D.B.5
Goldman, C.K.6
Brechbiel, M.W.7
Carrasquillo, J.A.8
Waldmann, T.A.9
-
122
-
-
84887362097
-
213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma
-
Ch?el M, Gouard S, Gaschet J et al. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J. Nucl. Med. 54, 1597-1604 (2013).
-
(2013)
J. Nucl. Med.
, vol.54
, pp. 1597-1604
-
-
Chel, M.1
Gouard, S.2
Gaschet, J.3
-
123
-
-
2542493831
-
213Bi-labeled domain-deleted humanized monoclonal antibody
-
DOI 10.1089/108497804323071904
-
Milenic D, Garmestani K, Dadachova E et al. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother. Radiopharm. 19, 135-147 (2004). (Pubitemid 38685111)
-
(2004)
Cancer Biotherapy and Radiopharmaceuticals
, vol.19
, Issue.2
, pp. 135-147
-
-
Milenic, D.1
Garmestani, K.2
Dadachova, E.3
Chappell, L.4
Albert, P.5
Hill, D.6
Schlom, J.7
Brechbiel, M.8
-
124
-
-
52649160241
-
Multimodality therapy potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease
-
Milenic DE, Garmestani K, Brady ED et al. Multimodality therapy. potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin. Cancer Res. 14, 5108-5115 (2008).
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 5108-5115
-
-
Milenic, D.E.1
Garmestani, K.2
Brady, E.D.3
-
125
-
-
76249102432
-
Improved efficacy of alpha-particletargeted radiation therapy: Dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72
-
Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particletargeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer 116(4 Suppl.), 1059-1066 (2010).
-
(2010)
Cancer
, vol.116
, Issue.4 SUPPL.
, pp. 1059-1066
-
-
Milenic, D.E.1
Brady, E.D.2
Garmestani, K.3
Albert, P.S.4
Abdulla, A.5
Brechbiel, M.W.6
-
126
-
-
84880858990
-
Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation
-
Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW. Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. Cancer Biother. Radiopharm. 28, 441-449 (2013).
-
(2013)
Cancer Biother. Radiopharm.
, vol.28
, pp. 441-449
-
-
Milenic, D.E.1
Baidoo, K.E.2
Shih, J.H.3
Wong, K.J.4
Brechbiel, M.W.5
-
127
-
-
20244384731
-
213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death
-
DOI 10.1007/s00259-004-1653-3
-
Seidl C, Schr?k H, Seidenschwang S et al. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur. J. Nucl. Med. Mol. Imaging 32, 274-285 (2005). (Pubitemid 40562118)
-
(2005)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.32
, Issue.3
, pp. 274-285
-
-
Seidl, C.1
Schrock, H.2
Seidenschwang, S.3
Beck, R.4
Schmid, E.5
Abend, M.6
Becker, K.-F.7
Apostolidis, C.8
Nikula, T.K.9
Kremmer, E.10
Schwaiger, M.11
Senekowitsch-Schmidtke, R.12
-
128
-
-
70349639994
-
Treatment of diffusetype gastric cancer cells using 213Bi- radioimmunoconjugates in vitro and in vivo following intraperitoneal dissemination
-
Seidl C, Senekowitsch-Schmidtke R. Treatment of diffusetype gastric cancer cells using 213Bi-radioimmunoconjugates in vitro and in vivo following intraperitoneal dissemination. Curr. Radiopharm. 1, 215-224 (2008).
-
(2008)
Curr. Radiopharm.
, vol.1
, pp. 215-224
-
-
Seidl, C.1
Senekowitsch-Schmidtke, R.2
-
129
-
-
0035300544
-
213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional α-radioimmunotherapy of diffuse-type gastric cancer
-
Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF et al. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res. 61, 2804-2808 (2001). (Pubitemid 32691914)
-
(2001)
Cancer Research
, vol.61
, Issue.7
, pp. 2804-2808
-
-
Senekowitsch-Schmidtke, R.1
Schuhmacher, C.2
Becker, K.-F.3
Nikula, T.K.4
Seidl, C.5
Becker, I.6
Miederer, M.7
Apostolidis, C.8
Adam, A.9
Huber, R.10
Kremmer, E.11
Fischer, K.12
Schwaiger, M.13
-
130
-
-
12444319923
-
Locoregional α-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody
-
Huber R, Seidl C, Schmid E et al. Locoregional alpharadioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clin. Cancer Res. 9(10 Pt 2), 3922s-3928s (2003). (Pubitemid 37169198)
-
(2003)
Clinical Cancer Research
, vol.9
, Issue.10
-
-
Huber, R.1
Seidl, C.2
Schmid, E.3
Seidenschwang, S.4
Becker, K.-F.5
Schuhmacher, C.6
Apostolidis, C.7
Nikula, T.8
Kremmer, E.9
Schwaiger, M.10
Senekowitsch-Schmidtke, R.11
-
131
-
-
34347251608
-
213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice
-
DOI 10.1111/j.1349-7006.2007.00525.x
-
Beck R, Seidl C, Pfost B et al. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci. 98, 1215-1222 (2007). (Pubitemid 46994574)
-
(2007)
Cancer Science
, vol.98
, Issue.8
, pp. 1215-1222
-
-
Beck, R.1
Seidl, C.2
Pfost, B.3
Morgenstern, A.4
Bruchertseifer, F.5
Baum, H.6
Schwaiger, M.7
Senekowitsch-Schmidtke, R.8
-
132
-
-
34249016349
-
213Bi-radioimmunotherapy using bioluminescence imaging
-
DOI 10.1007/s00259-006-0311-3
-
Buchhorn HM, Seidl C, Beck R et al. Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging. Eur. J. Nucl. Med. Mol. Imaging 34, 841-849 (2007). (Pubitemid 46798953)
-
(2007)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.34
, Issue.6
, pp. 841-849
-
-
Buchhorn, H.M.1
Seidl, C.2
Beck, R.3
Saur, D.4
Apostolidis, C.5
Morgenstern, A.6
Schwaiger, M.7
Senekowitsch-Schmidtke, R.8
-
133
-
-
26444446027
-
213Bi- conjugated monoclonal antibody
-
DOI 10.1158/1078-0432.CCR-1004-0017
-
Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody. Clin. Cancer Res. 11(19 Pt 2), 7070s-7074s (2005). (Pubitemid 41428706)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.19
-
-
Bloechl, S.1
Beck, R.2
Seidl, C.3
Morgenstern, A.4
Schwaiger, M.5
Senekowitsch-Schmidtke, R.6
-
134
-
-
84862613060
-
High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum
-
Rauch C, Seidl C, Schlapschy M et al. High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum. Nucl. Med. Biol. 39, 617-627 (2012).
-
(2012)
Nucl. Med. Biol.
, vol.39
, pp. 617-627
-
-
Rauch, C.1
Seidl, C.2
Schlapschy, M.3
-
135
-
-
79551513604
-
177Luimmunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi
-
Seidl C, Z?kler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F, Senekowitsch-Schmidtke R. 177Luimmunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi. Eur. J. Nucl. Med. Mol. Imaging 38, 312-322 (2011).
-
(2011)
Eur. J. Nucl. Med. Mol. Imaging
, vol.38
, pp. 312-322
-
-
Seidl, C.1
Zkler, C.2
Beck, R.3
Quintanilla-Martinez, L.4
Bruchertseifer, F.5
Senekowitsch-Schmidtke, R.6
-
136
-
-
34848840131
-
213Bi-C- functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy
-
DOI 10.1158/1078-0432.CCR-07-1071
-
Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyldiethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin. Cancer Res. 13(18 Pt 2), 5604s-5612s (2007). (Pubitemid 47510394)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.18
-
-
Kelly, M.P.1
Lee, F.T.2
Tahtis, K.3
Smyth, F.E.4
Brechbiel, M.W.5
Scott, A.M.6
-
137
-
-
2442474076
-
213Bi 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N-Tetraacetic Acid-Biotin
-
DOI 10.1158/1078-0432.CCR-03-0171
-
Yao Z, Zhang M, Garmestani K et al. Pretargeted alpha emitting radioimmunotherapy using 213Bi 1,4,7,10-tetraazacyclododecane-N,N',N", N"'-tetraacetic acidbiotin. Clin. Cancer Res. 10, 3137-3146 (2004). (Pubitemid 38619695)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.9
, pp. 3137-3146
-
-
Yao, Z.1
Zhang, M.2
Garmestani, K.3
Axworthy, D.B.4
Mallett, R.W.5
Fritzberg, A.R.6
Theodore, L.J.7
Plascjak, P.S.8
Eckelman, W.C.9
Waldmann, T.A.10
Pastan, I.11
Paik, C.H.12
Brechbiel, M.W.13
Carrasquillo, J.A.14
-
138
-
-
45549088490
-
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model
-
Song H, Shahverdi K, Huso DL et al. 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 68, 3873-3880 (2008).
-
(2008)
Cancer Res.
, vol.68
, pp. 3873-3880
-
-
Song, H.1
Shahverdi, K.2
Huso, D.L.3
-
139
-
-
77956279807
-
Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer
-
Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G. Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res. 70, 6815-6823 (2010).
-
(2010)
Cancer Res.
, vol.70
, pp. 6815-6823
-
-
Lingappa, M.1
Song, H.2
Thompson, S.3
Bruchertseifer, F.4
Morgenstern, A.5
Sgouros, G.6
-
140
-
-
61349165644
-
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted alpha radioimmunoconjugates
-
Li Y, Song E, Abbas Rizvi SM et al. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Clin. Cancer Res. 15, 865-875 (2009).
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 865-875
-
-
Li, Y.1
Song, E.2
Abbas Rizvi, S.M.3
-
141
-
-
84861717772
-
Orthotopic administration of 213Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate
-
Rizvi S, Allen B, Lee C et al. Orthotopic administration of 213Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate. Immunotherapy 4, 549-554 (2012).
-
(2012)
Immunotherapy
, vol.4
, pp. 549-554
-
-
Rizvi, S.1
Allen, B.2
Lee, C.3
-
142
-
-
42549102773
-
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
-
Song EY, Qu CF, Rizvi SM et al. Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol. Ther. 7, 76-80 (2008). (Pubitemid 351590456)
-
(2008)
Cancer Biology and Therapy
, vol.7
, Issue.1
, pp. 76-80
-
-
Song, E.Y.1
Qu, C.F.2
Rizvi, S.M.A.3
Raja, C.4
Beretov, J.5
Morgenstern, A.6
-
143
-
-
70349644860
-
Intravesical alpharadioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice
-
Pfost B, Seidl C, Autenrieth M et al. Intravesical alpharadioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J. Nucl. Med. 50, 1700-1708 (2009).
-
(2009)
J. Nucl. Med.
, vol.50
, pp. 1700-1708
-
-
Pfost, B.1
Seidl, C.2
Autenrieth, M.3
-
144
-
-
1842714861
-
149Tb-rituximab
-
Beyer GJ, Miederer M, Vranjes-Duri? S et al. Targeted alpha therapy in vivo. direct evidence for single cancer cell kill using 149Tb-rituximab. Eur. J. Nucl. Med. Mol. Imaging 31, 547-554 (2004). (Pubitemid 38461571)
-
(2004)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.31
, Issue.4
, pp. 547-554
-
-
Beyer, G.-J.1
Miederer, M.2
Vranjes-Duric, S.3
Comor, J.J.4
Kunzi, G.5
Hartley, O.6
Senekowitsch-Schmidtke, R.7
Soloviev, D.8
Buchegger, F.9
-
145
-
-
34548829082
-
Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate
-
DOI 10.1182/blood-2007-01-066803
-
Dahle J, Borrebaek J, Jonasdottir TJ et al. Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate. Blood 110, 2049-2056 (2007). (Pubitemid 47443922)
-
(2007)
Blood
, vol.110
, Issue.6
, pp. 2049-2056
-
-
Dahle, J.1
Borrebaek, J.2
Jonasdottir, T.J.3
Hjelmerud, A.K.4
Melhus, K.B.5
Bruland, O.S.6
Press, O.W.7
Larsen, R.H.8
-
146
-
-
49749151055
-
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and betaemitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
-
Dahle J, Bruland OS, Larsen RH. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and betaemitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. Int. J. Radiat. Oncol. Biol. Phys. 72, 186-192 (2008).
-
(2008)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.72
, pp. 186-192
-
-
Dahle, J.1
Bruland, O.S.2
Larsen, R.H.3
-
147
-
-
72949096312
-
Assessment of long-term radiotoxicity after treatment with the lowdose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab
-
Dahle J, Jonasdottir TJ, Heyerdahl H et al. Assessment of long-term radiotoxicity after treatment with the lowdose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab. Eur. J. Nucl. Med. Mol. Imaging 37, 93-102 (2010).
-
(2010)
Eur. J. Nucl. Med. Mol. Imaging
, vol.37
, pp. 93-102
-
-
Dahle, J.1
Jonasdottir, T.J.2
Heyerdahl, H.3
-
148
-
-
84864531160
-
Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab
-
Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS ONE 7, e42345 (2012).
-
(2012)
PLoS ONE
, vol.7
-
-
Heyerdahl, H.1
Abbas, N.2
Brevik, E.M.3
Mollatt, C.4
Dahle, J.5
-
149
-
-
84875912243
-
Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTAtrastuzumab
-
Abbas N, Heyerdahl H, Bruland OS, Borreb? J, Nesland J, Dahle J. Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTAtrastuzumab. EJNMMI Res. 1, 18 (2011).
-
(2011)
EJNMMI Res.
, vol.1
, Issue.18
-
-
Abbas, N.1
Heyerdahl, H.2
Bruland, O.S.3
Borreb, J.4
Nesland, J.5
Dahle, J.6
-
150
-
-
84891398251
-
Comparing high LET 227Th-and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts
-
Abbas N, Heyerdahl H, Bruland ?S, Brevik EM, Dahle J. Comparing high LET 227Th-and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts. Curr. Radiopharm. 6, 78-86 (2013).
-
(2013)
Curr. Radiopharm.
, vol.6
, pp. 78-86
-
-
Abbas, N.1
Heyerdahl, H.2
Bruland, S.3
Brevik, E.M.4
Dahle, J.5
-
151
-
-
84891385840
-
Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice
-
Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland ?, Dahle J. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice. Curr. Radiopharm. 6, 106-116 (2013).
-
(2013)
Curr. Radiopharm.
, vol.6
, pp. 106-116
-
-
Heyerdahl, H.1
Abbas, N.2
Sponheim, K.3
Mollatt, C.4
Bruland, D.J.5
-
152
-
-
84881375764
-
Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting 227Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts
-
Heyerdahl H,Brevik EM, Dahle J. Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting 227Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts. Int. J. Radiat. Oncol. Biol. Phys. 87, 153-159 (2013).
-
(2013)
Int. J. Radiat. Oncol. Biol. Phys.
, vol.87
, pp. 153-159
-
-
Heyerdahl, H.1
Brevik, E.M.2
Dahle, J.3
-
153
-
-
84863490194
-
Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
-
Abbas N, Bruland ?S, Brevik EM, Dahle J. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts. Nucl. Med. Commun. 33, 838-847 (2012).
-
(2012)
Nucl. Med. Commun.
, vol.33
, pp. 838-847
-
-
Abbas, N.1
Bruland, S.2
Brevik, E.M.3
Dahle, J.4
-
154
-
-
24944554605
-
Immunotherapy for acute myeloid leukemia
-
Jurcic JG. Immunotherapy for acute myeloid leukemia. Curr. Oncol. Rep. 7, 339-346 (2005). (Pubitemid 41309549)
-
(2005)
Current Oncology Reports
, vol.7
, Issue.5
, pp. 339-346
-
-
Jurcic, J.G.1
-
155
-
-
37649010802
-
Clinical experience with alpha-particle emitting 211At treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
-
Zalutsky MR, Reardon DA, Akabani G et al. Clinical experience with alpha-particle emitting 211At. treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 49, 30-38 (2008).
-
(2008)
J. Nucl. Med.
, vol.49
, pp. 30-38
-
-
Zalutsky, M.R.1
Reardon, D.A.2
Akabani, G.3
-
156
-
-
67650088549
-
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients pharmacokinetics and dosimetry of 211At-MX35 F(ab')2-a Phase i study
-
Andersson H, Cederkrantz E, B?k T et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients. pharmacokinetics and dosimetry of 211At-MX35 F(ab')2-a Phase I study. J. Nucl. Med. 50, 1153-2260 (2009).
-
(2009)
J. Nucl. Med.
, vol.50
, pp. 1153-2260
-
-
Andersson, H.1
Cederkrantz, E.2
Bk, T.3
-
157
-
-
84890532810
-
Pharmacokinetics and Imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients
-
Meredith RF, Torgue J, Azure MT et al. Pharmacokinetics and Imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother. Radiopharm. 29(1), 12-17 (2014).
-
(2014)
Cancer Biother. Radiopharm.
, vol.29
, Issue.1
, pp. 12-17
-
-
Meredith, R.F.1
Torgue, J.2
Azure, M.T.3
-
159
-
-
25144500525
-
Phase i clinical study on alpha-therapy for non Hodgkin lymphoma
-
D?seldorf, Germany, 28-29 June 2004 Morgenstern A (Ed.):Institute for Transuranium Elements, Karlsruhe, Germany, 11
-
Schmidt D, Neumann F, Antke C et al. Phase I clinical study on alpha-therapy for non Hodgkin lymphoma. In: Proceedings of the 4th alpha-Immunotherapy Symposium. D?seldorf, Germany, 28-29 June 2004; Morgenstern A (Ed.): Institute for Transuranium Elements, Karlsruhe, Germany, 11 (2004). http://itu.jrc.ec.europa.eu/index.php?id=205
-
(2004)
Proceedings of the 4th Alpha-Immunotherapy Symposium
-
-
Schmidt, D.1
Neumann, F.2
Antke, C.3
-
160
-
-
0037103293
-
Targeted α particle immunotherapy for myeloid leukemia
-
Jurcic JG, Larson SM, Sgouros G et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100, 1233-1239 (2002). (Pubitemid 34864277)
-
(2002)
Blood
, vol.100
, Issue.4
, pp. 1233-1239
-
-
Jurcic, J.G.1
Larson, S.M.2
Sgouros, G.3
McDevitt, M.R.4
Finn, R.D.5
Divgi, C.R.6
Ballangrud, A.M.7
Hamacher, K.A.8
Ma, D.9
Humm, J.L.10
Brechbiel, M.W.11
Molinet, R.12
Scheinberg, D.A.13
-
161
-
-
78049456138
-
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
-
Rosenblat TL, McDevitt MR, Mulford DA et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res. 16, 5303-5311 (2010).
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 5303-5311
-
-
Rosenblat, T.L.1
McDevitt, M.R.2
Mulford, D.A.3
-
162
-
-
31144463014
-
Intralesional targeted alpha therapy for metastatic melanoma
-
Allen BJ, Raja C, Rizvi S et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 4, 1318-1324 (2005). (Pubitemid 43131174)
-
(2005)
Cancer Biology and Therapy
, vol.4
, Issue.12
, pp. 1318-1324
-
-
Allen, B.J.1
Raja, C.2
Rizvi, S.3
Li, Y.4
Tsui, W.5
Graham, P.6
Thompson, J.F.7
Reisfeld, R.A.8
Kearsley, J.9
-
163
-
-
80053000534
-
Analysis of patient survival in a Phase i trial of systemic targeted α-therapy for metastatic melanoma
-
Allen BJ, Singla AA, Rizvi SM et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy 3, 1041-1050 (2011).
-
(2011)
Immunotherapy
, vol.3
, pp. 1041-1050
-
-
Allen, B.J.1
Singla, A.A.2
Rizvi, S.M.3
-
164
-
-
10644227867
-
Cyclotron production of Ac-225 for targeted alpha therapy
-
DOI 10.1016/j.apradiso.2004.06.013, PII S096980430400435X
-
Apostolidis C, Molinet R, McGinley J, Abbas K, M?lenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl. Radiat. Isot. 62, 383-387 (2005). (Pubitemid 39655916)
-
(2005)
Applied Radiation and Isotopes
, vol.62
, Issue.3
, pp. 383-387
-
-
Apostolidis, C.1
Molinet, R.2
McGinley, J.3
Abbas, K.4
Mollenbeck, J.5
Morgenstern, A.6
-
165
-
-
79959441137
-
Modelling and dosimetry for alpha-particle therapy
-
Sgouros G, Hobbs RF, Song H. Modelling and dosimetry for alpha-particle therapy. Curr. Radiopharm. 4, 261-265 (2011).
-
(2011)
Curr. Radiopharm.
, vol.4
, pp. 261-265
-
-
Sgouros, G.1
Hobbs, R.F.2
Song, H.3
-
167
-
-
79959437613
-
Alpha-particle microdosimetr
-
Chouin N, Bardies M. Alpha-particle microdosimetry. Curr. Radiopharm. 4, 266-280 (2011).
-
(2011)
Curr. Radiopharm.
, vol.4
, pp. 266-280
-
-
Chouin, N.1
Bardies, M.2
-
169
-
-
66349137472
-
Treatment of peritoneal carcinomatosis by targeted delivery of the radiolabeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells
-
Drecoll E, Gaertner FC, Miederer M et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radiolabeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS ONE 4, e5715 (2009).
-
(2009)
PLoS ONE
, vol.4
-
-
Drecoll, E.1
Gaertner, F.C.2
Miederer, M.3
-
170
-
-
84862557219
-
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumourhoming peptides in a preclinical mouse model of peritoneal carcinomatosis
-
Essler M, G?tner FC, Neff F et al. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumourhoming peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur. J. Nucl. Med. Mol. Imaging 39, 602-612 (2012).
-
(2012)
Eur. J. Nucl. Med. Mol. Imaging
, vol.39
, pp. 602-612
-
-
Essler, M.1
Gtner, F.C.2
Neff, F.3
-
171
-
-
84869094925
-
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest
-
Vallon M, Seidl C, Blechert B et al. Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest. Eur. J. Nucl. Med. Mol. Imaging 39, 1886-1897 (2012).
-
(2012)
Eur. J. Nucl. Med. Mol. Imaging
, vol.39
, pp. 1886-1897
-
-
Vallon, M.1
Seidl, C.2
Blechert, B.3
-
172
-
-
33745697736
-
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P
-
DOI 10.1158/1078-0432.CCR-05-2820
-
Kneifel S, Cordier D, Good S et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin. Cancer Res. 12, 3843-3850 (2006). (Pubitemid 44000266)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.12
, pp. 3843-3850
-
-
Kneifel, S.1
Cordier, D.2
Good, S.3
Ionescu, M.C.S.4
Ghaffari, A.5
Hofer, S.6
Kretzschmar, M.7
Tolnay, M.8
Apostolidis, C.9
Waser, B.10
Arnold, M.11
Mueller-Brand, J.12
Maecke, H.R.13
Reubi, J.C.14
Merlo, A.15
-
173
-
-
77954952365
-
Targeted alpharadionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: A pilot trial
-
Cordier D, Forrer F, Bruchertseifer F et al. Targeted alpharadionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2) 11]-substance P: a pilot trial. Eur. J. Nucl. Med. Mol. Imaging 37, 1335-1344 (2010).
-
(2010)
Eur. J. Nucl. Med. Mol. Imaging
, vol.37
, pp. 1335-1344
-
-
Cordier, D.1
Forrer, F.2
Bruchertseifer, F.3
-
174
-
-
79551553871
-
Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model 213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
-
Wild D, Frischknecht M, Zhang H et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model 213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 71, 1009-1018 (2011).
-
(2011)
Cancer Res.
, vol.71
, pp. 1009-1018
-
-
Wild, D.1
Frischknecht, M.2
Zhang, H.3
-
175
-
-
36849005923
-
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer
-
DOI 10.1007/s00259-007-0582-3
-
Kn S, Sato S, Huber T et al. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alphaemitter therapy for disseminated ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 53-64 (2008). (Pubitemid 350234153)
-
(2008)
European Journal of Nuclear Medicine and Molecular Imaging
, vol.35
, Issue.1
, pp. 53-64
-
-
Knor, S.1
Sato, S.2
Huber, T.3
Morgenstern, A.4
Bruchertseifer, F.5
Schmitt, M.6
Kessler, H.7
Senekowitsch-Schmidtke, R.8
Magdolen, V.9
Seidl, C.10
-
176
-
-
84856212043
-
Pretargeted radioimmunotherapy of colorectal cancer metastases models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide
-
Frampas E, Maurel C, Remaud-Le Sa? P et al. Pretargeted radioimmunotherapy of colorectal cancer metastases. models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide. Eur. J. Nucl. Med. Mol. Imaging 38, 2153-2164 (2011).
-
(2011)
Eur. J. Nucl. Med. Mol. Imaging
, vol.38
, pp. 2153-2164
-
-
Frampas, E.1
Maurel, C.2
Remaud-Le Sa, P.3
-
177
-
-
79959426898
-
Pretargeted radioimmunotherapy with α-particle emitting radionuclides
-
Lindegren S, Frost SH. Pretargeted radioimmunotherapy with α-particle emitting radionuclides. Curr. Radiopharm. 4, 248-260 (2011).
-
(2011)
Curr. Radiopharm.
, vol.4
, pp. 248-260
-
-
Lindegren, S.1
Frost, S.H.2
|